<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04064437</url>
  </required_header>
  <id_info>
    <org_study_id>2019-4550</org_study_id>
    <nct_id>NCT04064437</nct_id>
  </id_info>
  <brief_title>Prevalence of Vertebral Fractures in Patients With Type 1 Diabetes</brief_title>
  <acronym>DenSiFy</acronym>
  <official_title>Prevalence of Vertebral Fractures in Patients With Type 1 Diabetes (Diabetes Spine Fractures, DenSiFy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background : Type 1 diabetes is associated with an increased risk of fractures. The
      mechanisms accounting for this bone fragility are not yet fully understood. The lower bone
      mineral density (BMD) observed in individuals with type 1 diabetes cannot solely explain the
      higher fracture incidence. Bone microarchitecture defects significantly contribute to bone
      fragility. Few studies assessed spine fractures in type 1 diabetes.

      This cross-sectional multicenter case-control study aims (1) to evaluate the prevalence of
      asymptomatic vertebral fractures in individuals with type 1 diabetes in comparison to age-
      and sex-matched healthy controls; (2) to compare individuals with diabetes with vertebral
      fractures and those without vertebral fracture using clinical, biochemical and radiological
      parameters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vertebral fracture detected with VFA</measure>
    <time_frame>Baseline</time_frame>
    <description>Vertebral Fracture Assessment (VFA) software of dual-energy X-ray absorptiometry (DXA scan) is used to identify vertebral fractures. If there is evidence of a vertebral fracture on VFA, a lateral and anteroposterior spine X-ray will be obtained to confirm the VFA results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of the spine in g/cm2</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of the spine, T-score</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of the spine, Z-score</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of proximal femur in g/cm2</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of proximal femur, T-score</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of proximal femur, Z-score</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of total hip in g/cm2</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of total hip, T-score</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of total hip, Z-score</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of distal radius in g/cm2</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of distal radius, T-score</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of distal radius, Z-score</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean mass (arm, leg, trunk, android, gynoid and total)</measure>
    <time_frame>Baseline</time_frame>
    <description>Body composition measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass (arm, leg, trunk, android, gynoid and total)</measure>
    <time_frame>Baseline</time_frame>
    <description>Body composition measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin AGE measurement</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by AGE Reader</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-telopeptide</measure>
    <time_frame>Baseline</time_frame>
    <description>Bone turnover marker (serum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sclerostin</measure>
    <time_frame>Baseline</time_frame>
    <description>Bone turnover marker (serum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>Baseline</time_frame>
    <description>Bone turnover marker (serum)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HbA1C</measure>
    <time_frame>Baseline</time_frame>
    <description>Diabetes control marker</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Creatinine</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid panel</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Thyroid-stimulating hormone (TSH)</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Calcium</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Albumine</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Phosphate</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>25-Hydroxyvitamin D</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Parathormone (PTH)</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin like growth factor-1 (IGF-1)</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Antitransglutaminase antibodies</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunoglobulin A (IgA)</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Follicle stimulating hormone (FSH, women)</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Total testosterone (men)</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Sex hormone-binding globulin (SHBG, men)</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood level measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Microalbuminuria</measure>
    <time_frame>Baseline</time_frame>
    <description>Urine microalbuminuria / urine creatinine ratio measurement</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">191</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Bone Fracture</condition>
  <condition>Bone Health</condition>
  <arm_group>
    <arm_group_label>Individuals with type 1 diabetes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Clinical tests</intervention_name>
    <description>The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.</description>
    <arm_group_label>Individuals with type 1 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Clinical tests</intervention_name>
    <description>The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.</description>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biochemical tests</intervention_name>
    <description>The investigators perform blood and urine tests in every participant.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Individuals with type 1 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DXA scan</intervention_name>
    <description>The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Individuals with type 1 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>AGE Reader</intervention_name>
    <description>The investigators perform a skin AGE (advanced glycation end products) measurement with the AGE Reader machine in every participant.</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Individuals with type 1 diabetes</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (serum and plasma)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        127 individuals with type 1 diabetes and 64 healthy subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Individuals with type 1 diabetes

        Inclusion Criteria:

          -  Diagnosis of type 1 diabetes for at least 5 years;

          -  Age 20 years and older.

        Exclusion Criteria:

          -  Pregnancy or breastfeeding;

          -  Conditions associated with bone disease (significant liver disease, intestinal
             malabsorption other than celiac disease, organ transplant, active cancer, rheumatoid
             arthritis, hyperthyroidism, hypothyroidism with abnormal TSH, hyperparathyroidism,
             hypoparathyroidism, acromegaly, Cushing syndrome, adrenal insufficiency);

          -  Any of these medications in the past 6 months : glucocorticoids ≥ 7,5 mg
             prednisone/day or equivalency ≥ 3 months, aromatase inhibitors, antiandrogens,
             antiepileptic drugs, anticoagulants, SGLT-2 (sodium-glucose cotransporter-2)
             inhibitors, thiazolidinediones;

          -  Past medical history of traumatic vertebral fracture;

          -  Inability to consent.

        Healthy controls

        Inclusion Criteria:

          -  Age 20 years and older.

        Exclusion Criteria:

          -  As above (as individuals with diabetes), and :

          -  Diagnosis of diabetes or prediabetes;

          -  Celiac disease;

          -  Chronic kidney disease (CrCl &lt; 60 mL/min);

          -  Any of theses medications in the past 6 months : biphosphonates, teriparatide,
             denosumab, calcitonin;

          -  Past medical history of fragility fracture.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Gagnon, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec - Université Laval</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Chouinard-Castonguay</last_name>
    <phone>418-525-4444</phone>
    <phone_ext>48729</phone_ext>
    <email>Sarah.Chouinard-Castonguay@crchudequebec.ulaval.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de recherches cliniques de Montréal (IRCM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Mignault</last_name>
      <phone>514-987-5568</phone>
      <email>Diane.Mignault@ircm.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du CHU de Québec - Université Laval</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Chouinard-Castonguay</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>48729</phone_ext>
      <email>Sarah.Chouinard-Castonguay@crchudequebec.ulaval.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 17, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Claudia Gagnon</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Spinal Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

